Effects of Ezetimibe/Simvastatin 10/20 mg vs. Atorvastatin 20 mg on Apolipoprotein B/Apolipoprotein A1 in Korean Patients with Type 2 Diabetes Mellitus: Results of a Randomized Controlled Trial

Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance

(2012) Mark Naples et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Ezetimibe Ameliorates Atherosclerotic and Inflammatory Markers, Atherogenic Lipid Profiles, Insulin Sensitivity, and Liver Dysfunction in Japanese Patients with Hypercholesterolemia

(2012) Noboru Tamaki et al.   Journal of Atherosclerosis and Thrombosis

Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance

(2011) E. Moutzouri et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Atorvastatin 10mg plus ezetimibe 10mg compared with atorvastatin 20mg: Impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease

(2011) Yusuke Uemura et al.   Journal of Cardiology

Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)

(2011) Jennifer G. Robinson et al.   Journal of Clinical Lipidology

Patterns of cholesterol metabolism: Pathophysiological and therapeutic implications for dyslipidemias and the metabolic syndrome

(2011) G. Lupattelli et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Relationships Between Metabolic Syndrome and Other Baseline Factors and the Efficacy of Ezetimibe/Simvastatin and Atorvastatin in Patients With Type 2 Diabetes and Hypercholesterolemia

(2010) R. B. Goldberg et al.   DIABETES CARE

Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus

(2010) Kenta Okada et al.   ENDOCRINE JOURNAL

Pleiotropic Effects With Equivalent Low-density Lipoprotein Cholesterol Reduction: Comparative Study Between Simvastatin and Simvastatin/Ezetimibe Coadministration

(2010) Daniel B Araujo et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Effects of Atorvastatin 20 mg, Rosuvastatin 10 mg, and Atorvastatin/Ezetimibe 5 mg/5 mg on Lipoproteins and Glucose Metabolism

(2010) Ae-Young Her et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet

(2010) Tomonori Muraoka et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither

(2009) S. Conard et al.   DIABETES OBESITY & METABOLISM

The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls

(2009) S. Parish et al.   EUROPEAN HEART JOURNAL

Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia

(2009) André J Tremblay et al.   JOURNAL OF LIPID RESEARCH

Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors

(2008) Z. Ravid et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population

(2008) J. Sierra-Johnson et al.   EUROPEAN HEART JOURNAL

Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes

(2008) John R. Guyton et al.   Journal of Clinical Lipidology

Lipoprotein Management in Patients With Cardiometabolic Risk

(2008) John D. Brunzell et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY